#1Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration no. 333-260029 Relating to Preliminary Prospectus dated October 25, 2021 DIAGNOSTICS#2Issuer Free Writing Prospectus, Cautionary Statement Concerning Forward-looking Statements CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to obtain additional funding to develop our product candidates; our ability to satisfy any requirements imposed by the FDA (or its foreign equivalents); the impact of COVID-19 on our clinical trials, preclinical activities and our ability to raise future financing; our ability to continue our relationship with Toray; the need to obtain and retain regulatory approval of our products, both in the United States and in countries deemed necessary for future trials; our ability to complete our clinical trials in a timely fashion and within our expected budget and resources; compliance with obligations under intellectual property licenses with third parties; our ability to commercialize our product candidates; market acceptance of our products; and our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our products. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur. bluejay Copyright ©2021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 2#3Statement About Free Writing Prospectus This free writing prospectus relates to the proposed initial public offering of common stock of Bluejay Diagnostics, Inc., which are being registered on a registration statement on Form S-1 (File No. 333-260029) (the "Registration Statement"). This free writing prospectus should be read together with the preliminary prospectus dated October 25, 2021 included in the Registration Statement (the "Preliminary Prospectus"), which can be accessed through the following link: https://www.sec.gov/Archives/edgar/data/0001704287/000121390021054486/fs12021a1_bluejay.htm We have filed a Registration Statement, including the Preliminary Prospectus, with the SEC with respect to the offering of our securities to which this communication relates. The Registration Statement has not yet become effective. Before you invest, you should read the Preliminary Prospectus (including the risk factors described therein) and, when available, the final prospectus relating to the offering, and the other documents filed with the SEC, for more complete information about us and the offering. You may obtain these documents, including the Preliminary Prospectus, for free by visiting EDGAR on the SEC website at http://www.sec.gov. Alternatively, the company or the underwriter for the offering will arrange to send you the Preliminary Prospectus and, when available, the final prospectus and/or any supplements thereto, if you contact Dawson James Securities, Inc. at 101NFederal Hwy,Suite600, Boca Raton, FL,33432 by e-mail at [email protected] or by telephone at (561)391-5555. bluejay Copyright 22021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 3#4Symphery bluejay Srdey The Symphony System Bluejay Diagnostics is focused on improving patient outcomes in critical care settings using Symphony: Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance#5Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings Using Symphony, a cost efficient, rapid, near-patient product for triage, diagnosis and monitoring of disease progression Key Investment Highlights Physicians need high-sensitivity near-patient testing for triage/treatment guidance in critical care settings Symphony System has the potential to enable physicians to make better treatment decisions IL-6 Test for Sepsis Triage leads a pipeline targeting a potential multi-billion-dollar market opportunity Marketed in Japan for 3years by collaborator Toray** as "Research Use Only" product FDA 510(k) application for the IL-6 Test for Sepsis Triage planned for late Q3:22 bluejay LTAC-Long Term Acute Care "Toray Industries, Inc. Plan to expand the testing menu to include other well- validated critical care biomarkers Developed by Toray** through an extensive 12-year program & Bluejay has exclusive ex-Japan global rights Attractive recurring revenue model and a focused marketing plan to support the launch Led by a Team of healthcare and diagnostics veterans IPO proceeds to support development and marketing of IL-6 for Sepsis Triage Copyright 2021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 5#6The Symphony System: Technology Platform Analyzer and Cartridge basics The Symphony Analyzer Touch Panel Display 12.5 in 14.5 in 10.5 in bligay Printer Cartridge Insertion Slot (1-6) Same operational matrix irrespective of the test performed Same detection method .6 different samples or 6 different tests, simultaneously Symphony Cartridge Wastel Waste2 ::bluejay 150μl HIGH- Symphony Low- IL-6 Actual size No additional chemicals No pre-processing of the sample ELISA = Enzyme-Linked Immunosorbent Assay The Symphony platform will be leveraged by developing tests for other indications bluejay Copyright (02021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 6#7Lengthy Testing Time Reduces Utility for Triage/Treatment Guidance For use in hospital/long-term acute care (LTAC**) settings to provide triage/treatment guidance Physician orders the test ܦܐ Patient (critical care setting) Blood is drawn Physician uses the test results to triage/monitor patients and guide treatment *Source: Bluejay Diagnostics market research Blood is transported to testing site "LTAC-Long Term Acute Care Lab results are reported back to the physician Current Testing Methods: Testing systems are very large, so they need to be run in a central lab setting The whole process, from blood draw to results, takes 8-48hr- this is a long time in a critical care setting Systems require highly trained, expensive laboratory technicians to operate and maintain them bluejay Test is run at central testing site Hospital Testing Lab Copyright ©2021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 7#8Symphony Transforms Care Through Rapid, Near-Patient Testing Enables Physicians to make better treatment decisions for patients with life-threatening illnesses Physician orders the test Blood is drawn I Patient (ICU/long-term care setting) Physician uses the test results to triage/monitor patients and guide treatment Symphony Desk- Top System Symphony's Differentiated Features: The System can test whole blood samples (without the need for any pre-test processing) Symphony is a desk-top system, so tests can be run in critical care settings, near the patient's beside Results are provided quickly to make triage/treatment decisions (time to results -24 minutes) bluejay Test is run at/near the bedside Time to results -24 minutes Copyright (02021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 8#9Symphony System Potential Advantages* Uses well-accepted ELISA** chemistry plus unique microfluidics/nanotechnology platform Potential Advantages Testing Location Test System Size Sample type Sample Pre-process Time from test to result Staffing System Cost Cost per Test* Revenue Model bluejay Source: Bluejay Diagnostics market research Bluejay's Symphony Near patient Desk Top Whole blood No ~24 minutes No dedicated personnel (phlebotomist, Med Tech) $ $80 Reagent Rental **ELISA - Enzyme-Linked Immunosorbent Assay Major Diagnostic Manufacturers Central lab Very Large Plasma/Serum Yes 8-48hr Requires a Phlebotomist, Med Tech $$$ $275 System Purchase Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 9#10Symphony Product Pipeline Targets Multi-Billion Dollar Markets* Plan to expand the testing menu to include other well-validated critical care biomarkers Product Pipeline Commercial Rights Symphony ™M IL-6 Sepsis Triage Bluejay Diagnostics SymphonyTM hsTNT/I Triage Bluejay Diagnostics and Toray Industries SymphonyTM NT- proBNP Triage Bluejay Diagnostics and Toray Industries Research bluejay Development *Source: Bluejay Diagnostics market research >> Clinical Testing >> Regulatory Estimated Market Opportunity* Hospitals: $925M + LTAC: $2-3B Ongoing investment in Symphony System to improve user interface and support user adoption New Tests Will Follow the IL-6 Development Pathway Hospitals: $3.6B Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 10#11First Product: IL-6 for Sepsis Triage Measuring IL-6 could help medical professionals make earlier and better triage/treatment decisions Interleukin-6 (IL-6) is a Principal Inflammatory Cytokine Released During Trauma or Infection IL-6 is an established marker of immune system activation Elevated in response to infection such as COVID-19 and sepsis Also important in autoimmune disorders, such as rheumatoid arthritis (RA), cardiovascular diseases and all cancers bluejay *RUO-Research Use Only IL-6 needs to be measured quickly and reliably It appears early on as a "first responder" during infection or inflammation Reliably measuring IL-6 levels could help medical professionals triage, diagnose and monitor disease progression Current tests have received Emergency Use Authorization (EUA) for use in COVID-19 sepsis/RUO* for arthritis Beckman-Coulter, Roche and Siemens (EUA: COVID-sepsis) and Toray (RUO: arthritis) Tests are run in a central lab setting Estimated time from blood draw to results: 8-48hr IL-6 stability and turn-around time has limited adoption and utilization Copyright (02021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 11#12IL-6 is Following Well Established Clinical Testing Pathway Studies will document Symphony performance versus standard of care Elements of Clinical Testing Program: Will be Completed by Q3:22 (using -250 subjects): Testing Program Testing Sites Reference Range Study Cut-Off Value Study Cut-Off Validation Study Analytical Testing Regulatory Plan Milestone UTSouthwestern Medical Center® Zale Lipshy Pavilion Hospital Initial Testing Program at UT Southwestern UT Southwestern Testing Program results form the basis of FDA Pre-submission application Conduct an expanded Testing Program File an FDA 510(K)* application for the use of IL-6 in sepsis "including Regulatory pathways ((5100K) or de nava), to be determined with FDA, or any other alterative paths bluejay Authorization, - Only, LDT - Test William P. Clements Jr. University Hospital Parkland Target Timing Underway January 2022 Q1-Q3:2022 Q3: 2022 Copyright (02021 Blunjay Diagnostics, Inc. All rights reserved in all slides | October 2021 12#13Market Entry: Symphony IL-6 Staged approach Deployment as we progress through our clinical trials STAGE I Laboratory Developed Tests • Selected deployment . Clinical labs and ICUS who would perform internal validation *Stage II remains an option bluejay STAGE II* EUA (COVID-19 Sepsis) • ICUS • COVID centers/labs Clinical labs STAGE III 510(k) Sepsis triage • Emergency Rooms Sepsis centers Cancer Centers . . Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 13#14Launch Plan Starts by Converting Bluejay's Test Sites to Commercial Sites Existing multi-location healthcare testing sites are built-in initial commercial customers Test site performance evaluation Stage 1 & Clinical studies Convert testing sites to Stage 2 commercial sites 론 Roll-out to the expanded sites within Stage 3 the hospital system, per standard internal lab CLIA/QC process Roll-out to wider customer base Stage 4 beyond the testing site system bluejay Waterfall Commercial Strategy Leveraging internal champions to drive adoption Bluejay's Revenue Model . Symphony Analyzer will be leased or sold Cartridges provide recurring revenue Copyright (02021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 14#15Manufacturing Overview Contract Manufacturing Agreements in Place with Toray and Sanyoseiko 'TORAY' Innovation by Chemistry SANYOSEIKO bluejay Multinational company with 96+ years of manufacturing experience Toray will manufacture cartridges for 3 years More than 50 years of global experience in medical devices manufacturing Manufacturing the Symphony Analyzer Manufacturing cartridges alongside Toray starting 2023 Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 15#16Management Bluejay is led by a team of industry veterans with years of diagnostic and product launch experience Indranil "Neil" Dey CEO and Co-founder Gordon Kinder CFO Jason Cook CTO Kevin Vance Chief Commercial Officer NanoHYBRIDS bluejay Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Head of business development - Western U.S. for MPATH, a $300 million business unit with 65 direct reports • Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK More than 15 years of experience in corporate finance. Started at Ernst & Young LLP in 2005 Founded Capella Financial Services in 2008 and has served as senior finance executive for variety of companies • BA in History from Kenyon College and MBA and MS in Accounting degrees from Northeastern University Responsible for Bluejay's product development and manufacturing 15+ years of experience in the field of POC and diagnostics product development Ph.D. in Biomedical Engineering from University of Texas at Austin In charge of Bluejay's worldwide direct sales and strategic partnerships Before joining Bluejay, served as Chief Business Development Executive for Vibra Healthcare BS, Industrial Engineering & Operations Research from U. of Mass Amherst; MBA, Western New England University 4 VIBRA HEALTHCARE IMPATHE 1 Imbri EY Bulding a better Copyright (2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 16#17Board of Directors* Douglas C. Wurth Chairman Indranil "Neil" Dey CEO Svetlana Dey Donald R. Chase Fred S. Zeidman 20 year career at J.P. Morgan Chase, including CEO of the International Private Bank and CEO of the Alternative Investments division of Asset Management General Counsel to Senator Robert Dole's 1996 Presidential Campaign, practiced law at Skadden, Arps, Meagher and Flom B.A Notre Dame University; J.D. University of Virginia School of Law Skadden 25+ years in healthcare industry (pharma & diagnostics) • Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary and MBA (Fulbright Scholar) from Cambridge University, UK More than 15 years of management experience in healthcare industry Co-founder of Bluejay, President & CEO of LMBRI LLC, Board Member of Laminar Pharma, Inc. Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years, President & CEO West Bank Corporation, Multi State Community Bank, Mass Chairman, NUVO Bank, DeNovo Bank, Springfield, Mass, Merchants Bank, Director Millyard Bank, N.H. Bachelor of Science Degree, Accounting, Western New England University, Springfield, Mass, 50+ years of corporate advisory experience Chairman Emeritus Gordian Group, Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University J.P.Morgan Imbri bluejay Gary Gemignani has agreed to join the Board upon the completion of the IPO IMPATH LAMINAR PHARMA merchants BANCSHARES INC westbank HOLOCAUST MUSEUM Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 17#18Finance Overview Invested Capital and Use of Proceeds* Total Invested Capital $9 MM including equity and convertible debentures bluejay Offering Raising $18MM (excluding the over-allotment) *See the S-1 document for a full set of financial information Use of Proceeds* To support development and marketing of IL-6 for Sepsis Triage Copyright ©2021 Bluejay Diagnostics. Inc. All rights reserved in all slides | October 2021 18#19Offering Overview Issuer Ticker/Exchange Capital Raise Terms Use of Proceeds Joint Book-running Managers bluejay BlueJay Diagnostics, Inc. BJDX/Nasdaq Capital Market $18,000,000+ 15% over-allotment option The public offering price per unit is $10.00. Each Unit Consists of: a) One share of our common stock b) one Class A warrant (the "Class A Warrants") to purchase one share of our common stock at an exercise price equal to $5.00 per share (or 50% of the unit offering price), exercisable until the fifth anniversary of the issuance date c) one Class B warrant (the "Class B Warrants," and together with the Class A Warrants, the "Warrants") to purchase one share of our common stock at an exercise price equal to $10.00 per share (or 100% of the unit offering price), exercisable until the fifth anniversary of the issuance date. d) Holders of Class B Warrants may exercise such warrants on a "cashless" basis upon the earlier of (i) 10 trading days from the issuance date of such warrant or (ii) the time when $10.0 million of volume is traded in our common stock, if the volume weighted average price ("VWAP") of our common stock on any trading day on or after the date of issuance fails to exceed the exercise price of the Class B Warrant. To obtain our initial 510(k) regulatory approval in the United States for our sepsis product candidate To market the Sepsis test and Symphony system and establish a distribution network across the United States; and The remainder for working capital and general corporate purposes. Dawson James Securities, Inc.& l-Bankers Direct, LLC Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 19#20Bluejay is Focused on Improving Patient Outcomes in Hospital/LTAC* Settings Using Symphony, a cost efficient, rapid, near-patient product candidate for triage, diagnosis and monitoring of disease progression Key Investment Highlights Advancing a novel & proprietary point of care diagnostic platform the Symphony System - for near term market availability Same proprietary instrument can be used for multiple clinical diagnostic tests and offers numerous competitive advantages Development path has been de-risked through 12+ years of development and 3+ years of clinical evaluation led by Toray Lead Symphony test is for IL-6 measurement for sepsis triage/monitoring Well established and diverse diagnostic market for all sepsis situations Existing IL-6 test options are reimbursed for a multi-billion dollar U.S. market A strong pipeline of new Symphony test applications in development will follow Strong near term value milestones targeted Experienced, successful leadership team well matched for commercial development of this product line bluejay TAC - Long Term Acute Care Toray Industries, Inc. Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 20#21Symphery blucjay Sey The Symphony System Bluejay Diagnostics is focused on improving patient outcomes in critical care settings using Symphony: Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance#22Contact Bluejay Diagnostics, Inc. X 360 Massachusetts Avenue, Suite 203, Acton, MA 01720 Toll-free: 844.327.7078 Main: 978.631.4884 [email protected]